• Users Online: 556
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 106  |  Issue : 2  |  Page : 98-103

Ranibizumab versus bevacizumab for controlling progression of diabetic macular edema with cataract surgery


Department of Ophthalmology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Correspondence Address:
Ahmed A Abdel Ghany
MD, Faculty of Medicine, Suez Canal University, Ismailia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7123/01.JEO.0000431546.80029.21

Rights and Permissions

Purpose

To evaluate the effect of an intravitreal injection of ranibizumab or bevacizumab for the management and control of diabetic macular edema (DME) with phacoemulsification.

Patients and methods

The study population included patients with diffuse DME associated with cataract. Preoperative best-corrected visual acuity (BCVA) was determined and recorded in log MAR and then preoperative assessment by fundus fluorescein angiography and optical coherence topography (OCT) was carried out and recorded. The patients were divided into two groups. For the first group, both phacoemulsification with posterior chamber intraocular lens implantation and an intravitreal injection of ranibizumab were performed, group A, and for the second group, both phacoemulsification with posterior chamber intraocular lens implantation and an intravitreal injection of bevacizumab were performed, group B. Four weeks postoperatively, BCVA in log MAR for each patient in each group was determined and recorded; postoperative fundus fluorescein angiography and assessment of the macular thickness with OCT were performed and recorded.

Results

This study included 30 eyes, 15 in each group; on the basis of the results, in group A, there was an improvement in macular edema and reduction in central macular thickness (CMT) postoperatively as the mean CMT preoperatively was 397.22±45.43 and improved postoperatively to 328.61±21.64. Also, BCVA improved from 0.96±0.11 to 0.49±0.2. In group B, there was an improvement in macular edema and a decrease in CMT postoperatively as the mean preoperative CMT was 401.8±74.54 and decreased postoperatively to 379.08±78.6; also, BCVA improved from 0.95±0.34 to 0.7±0.1.

Conclusion

From this study, we concluded that OCT should be performed for all diabetic patients who will undergo cataract surgery preoperatively to assess macular thickness and diagnose the presence of DME; also, both ranibizumab and bevacizumab play an important role in controlling DME with cataract surgery, with higher efficacy for ranibizumab than bevacizumab.



[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed753    
    Printed11    
    Emailed0    
    PDF Downloaded103    
    Comments [Add]    

Recommend this journal